Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: A systematic review

Archives of Internal Medicine

Volumn 163, Issue 11, 2003, Pages 1362-1366

  O'Donnell, Martin ^a,b   Linkins, Lori Ann ^a   Kearon, Clive ^a   Julian, Jim ^a   Hirsh, Jack ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HENDERSON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EMBASE; FATALITY; HIP ARTHROPLASTY; HOSPITAL DISCHARGE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK; STANDARDIZATION; SYMPTOM; THROMBOEMBOLISM; VEIN THROMBOSIS;

ARTHROPLASTY, REPLACEMENT, HIP; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

EID: 0038687344     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.11.1362     Document Type: Review

References (19)

1. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001;119(1 suppl):132S-175S.
2. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996;348:224-228.
3. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996;335:696-700.
4. Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty: the Danish Prolonged Prophylaxis (DaPP) Study. Thromb Res. 1998; 89:281-287.
5. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery: results of a double-blind, prospective, randomized, placebo-controlled study with dalteparin. Thromb Haemost. 1997;77:26-31.
6. Hull RD, Pineo GF, Francis C, et al. Low-molecular weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. Arch Intern Med. 2000;160:2208-2215.
7. Heit JA, Elliott CG, Trowbridge AA, Gent M, Hirsh J, for the Ardeparin Arthroplasty Study Group. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000;132:853-861.
8. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. J Bone Joint Surg Am. 2001;83:336-345,
9. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after hip or knee replacement: a meta-analysis of the randomised trials. Lancet. 2001;358:9-15.
10. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular weight heparin prophylaxis against deep vein thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001;135:858-869.
11. Cohen AT, Bailey CS, Alikham R, Cooper DJ. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty: a meta-analysis. Thromb Haemost. 2001;85:940-941.
12. Robinson KS, Anderson DR, Gross M, et al. Ultrasonic screening before hospital discharge for deep vein thrombosis after arthroplasty: the post-arthroplasty screening study: a randomised controlled trial. Ann Intern Med. 1997;127:439-445.
13. Leclerc JR, Gent M, Hirsh J, Ginsberg JS, Geerts WH. The incidence of venographic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study in patients who underwent hip or knee arthroplasty. Arch Intern Med. 1998;158:873-878.
14. Colwell CW, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am. 1999;81:932-940.
15. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998;158:1525-1531.
16. Zelen M. The analysis of several 2 x 2 contingency tables. Biometrika. 1971;58: 129-137.
17. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) Trial. Lancet. 2000;355:1295-1302.
18. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ. 1994;308:235-246.
19. Sarasin FP, Bounameaux H. Out of hospital antithrombotic prophylaxis after total hip replacement: low molecular weight heparin, warfarin, aspirin or nothing? Thromb Haemost. 2002;87:586-592.